January 20, 2026- For the tenth consecutive year, the Centers for Medicare & Medicaid Services (CMS) has named McKesson a Qualified Clinical Data Registry (QCDR) approved to participate in the Merit-based Incentive Payment System (MIPS).
As a CMS-approved QCDR, McKesson’s Practice Insights — a performance analytics tool powered by Ontada®, McKesson’s real-world oncology data and insights business — collects and reports clinical data for clinicians using the IKnowMed® electronic health record. The designation allows practices and providers to efficiently submit data for both MIPS and custom QCDR quality measures directly to CMS, eliminating the need for a separate registry vendor and reducing administrative burdens.
McKesson’s Practice Insights offers nine oncology-specific QCDR measures to drive improvements in quality and cost of care. Seven of these measures were developed in collaboration with physicians in The US Oncology Network, an organization of community-based providers supported by McKesson:
- Screening and Achieving Resolution or Improvement of Distress for Cancer Care
- Advance Care Planning in Metastatic Cancer Patients
- Patient-Reported Pain Improvement
- Supportive Care Drug Utilization in Last 14 Days of Life
- Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
- Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy
- Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy
Two additional measures were developed by the American Society of Clinical Oncology (ASCO) and have been approved for the fourth year:
- Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic — Avoidance of Overuse
- Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents
Additionally, CMS retained two Practice Insights QCDR measures for inclusion in the 2026 Advancing Cancer Care MIPS Value Pathways: Mutation Testing for Stage IV Lung Cancer and Utilization of Prophylactic GCSF for Patients Receiving Low-Risk Chemotherapy. This recognition underscores the value of McKesson’s quality measures for improving cancer care.
New for 2026 is a patient-reported outcome measure that tracks whether distress screening and follow-up interventions lead to meaningful improvement or resolution within six months. Distress includes physical, emotional, social, practical and spiritual concerns — key factors that affect patient well-being and treatment outcomes. By tracking this measure through McKesson’s Practice Insights’ QCDR, practices can gain insights into the effectiveness of psychosocial care, helping deliver timely interventions and enhanced patient support.